



Polo Like Kinase Inhibitors

Summary

Compounds in Phase II clinical development: *BI-2536*, Boehringer Ingelheim

Compounds in Phase I clinical development: *GSK-461364*, GSK; *ON01910*, Onconova; *BI-6727*, Boehringer Ingelheim; *HMN-214*, Nippon Shinyaku

Number of Compounds in Preclinical development: 25

Highest development stage for any active PLK inhibitor: Phase II

Highest development stage for any active or discontinued PLK inhibitor: Phase II

Number of companies or institutions working on PLK inhibitors: 26

Number of companies or institutions holding PLK patents: 49

Contents

1. Polo Like Kinase Inhibitors	2
2. Polo Like Kinase Patents and Research Programs	11
3. Pipeline and Patent Metrics	14
4. Search Criteria, Sources and Disclaimers	15